103 related articles for article (PubMed ID: 21718285)
1. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: the influence of nonionic surfactants.
Fischer SM; Flaten GE; Hagesæther E; Fricker G; Brandl M
J Pharm Pharmacol; 2011 Aug; 63(8):1022-30. PubMed ID: 21718285
[TBL] [Abstract][Full Text] [Related]
2. Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers.
Fischer SM; Brandl M; Fricker G
Eur J Pharm Biopharm; 2011 Oct; 79(2):416-22. PubMed ID: 21549839
[TBL] [Abstract][Full Text] [Related]
3. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier.
Kanzer J; Tho I; Flaten GE; Mägerlein M; Hölig P; Fricker G; Brandl M
J Pharm Pharmacol; 2010 Nov; 62(11):1591-8. PubMed ID: 21039543
[TBL] [Abstract][Full Text] [Related]
4. Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on the barrier integrity and on the permeability.
Flaten GE; Skar M; Luthman K; Brandl M
Eur J Pharm Sci; 2007 Mar; 30(3-4):324-32. PubMed ID: 17204409
[TBL] [Abstract][Full Text] [Related]
5. Application of simulated intestinal fluid on the phospholipid vesicle-based drug permeation assay.
Fischer SM; Buckley ST; Kirchmeyer W; Fricker G; Brandl M
Int J Pharm; 2012 Jan; 422(1-2):52-8. PubMed ID: 22027395
[TBL] [Abstract][Full Text] [Related]
6. Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes.
Flaten GE; Bunjes H; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jul; 28(4):336-43. PubMed ID: 16697561
[TBL] [Abstract][Full Text] [Related]
7. Development of a biomimetic phospholipid vesicle-based permeation assay for the estimation of intestinal drug permeability.
Naderkhani E; Isaksson J; Ryzhakov A; Flaten GE
J Pharm Sci; 2014 Jun; 103(6):1882-90. PubMed ID: 24665049
[TBL] [Abstract][Full Text] [Related]
8. Drug permeability across a phospholipid vesicle-based barrier 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability.
Flaten GE; Luthman K; Vasskog T; Brandl M
Eur J Pharm Sci; 2008 Jul; 34(2-3):173-80. PubMed ID: 18499410
[TBL] [Abstract][Full Text] [Related]
9. Enhancing effect of surfactants on fexofenadine.HCl transport across the human nasal epithelial cell monolayer.
Lin H; Gebhardt M; Bian S; Kwon KA; Shim CK; Chung SJ; Kim DD
Int J Pharm; 2007 Feb; 330(1-2):23-31. PubMed ID: 16997520
[TBL] [Abstract][Full Text] [Related]
10. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion.
Flaten GE; Dhanikula AB; Luthman K; Brandl M
Eur J Pharm Sci; 2006 Jan; 27(1):80-90. PubMed ID: 16246536
[TBL] [Abstract][Full Text] [Related]
11. Mixed micelle formation between amino acid-based surfactants and phospholipids.
Faustino CM; Calado AR; Garcia-Rio L
J Colloid Interface Sci; 2011 Jul; 359(2):493-8. PubMed ID: 21536301
[TBL] [Abstract][Full Text] [Related]
12. Mixed micelle formation with phosphatidylcholines: the influence of surfactants with different molecule structures.
Rupp C; Steckel H; Müller BW
Int J Pharm; 2010 Mar; 387(1-2):120-8. PubMed ID: 20005930
[TBL] [Abstract][Full Text] [Related]
13. In vitro models to estimate drug penetration through the compromised stratum corneum barrier.
Engesland A; Škalko-Basnet N; Flaten GE
Drug Dev Ind Pharm; 2016 Nov; 42(11):1742-51. PubMed ID: 27019078
[TBL] [Abstract][Full Text] [Related]
14. Estimation of effective intestinal membrane permeability considering bile micelle solubilisation.
Sugano K
Int J Pharm; 2009 Feb; 368(1-2):116-22. PubMed ID: 18992315
[TBL] [Abstract][Full Text] [Related]
15. Liposomes for (trans)dermal drug delivery: the skin-PVPA as a novel in vitro stratum corneum model in formulation development.
Palac Z; Engesland A; Flaten GE; Škalko-Basnet N; Filipović-Grčić J; Vanić Ž
J Liposome Res; 2014 Dec; 24(4):313-22. PubMed ID: 24646434
[TBL] [Abstract][Full Text] [Related]
16. Absorption of poorly water soluble drugs subject to apical efflux using phospholipids as solubilizers in the Caco-2 cell model.
Kapitza SB; Michel BR; van Hoogevest P; Leigh ML; Imanidis G
Eur J Pharm Biopharm; 2007 Apr; 66(1):146-58. PubMed ID: 17071065
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylcholine embedded micellar systems: enhanced permeability through rat skin.
Spernath A; Aserin A; Sintov AC; Garti N
J Colloid Interface Sci; 2008 Feb; 318(2):421-9. PubMed ID: 18005978
[TBL] [Abstract][Full Text] [Related]
18. Characterization and evaluation of a modified PVPA barrier in comparison to Caco-2 cell monolayers for combined dissolution and permeation testing.
Gantzsch SP; Kann B; Ofer-Glaessgen M; Loos P; Berchtold H; Balbach S; Eichinger T; Lehr CM; Schaefer UF; Windbergs M
J Control Release; 2014 Feb; 175():79-86. PubMed ID: 24361370
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the hydrophobic effect. 2. A computer simulation-molecular-thermodynamic model for the micellization of nonionic surfactants in aqueous solution.
Stephenson BC; Goldsipe A; Beers KJ; Blankschtein D
J Phys Chem B; 2007 Feb; 111(5):1045-62. PubMed ID: 17266258
[TBL] [Abstract][Full Text] [Related]
20. Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant.
Sheng JJ; Kasim NA; Chandrasekharan R; Amidon GL
Eur J Pharm Sci; 2006 Nov; 29(3-4):306-14. PubMed ID: 16982177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
